 Marie Burdine
Concepts (182)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| DNA-Activated Protein Kinase | 5 | 2024 | 21 | 3.250 |
Why?
| | Chromones | 2 | 2024 | 16 | 1.620 |
Why?
| | Morpholines | 2 | 2024 | 65 | 1.570 |
Why?
| | DNA-Binding Proteins | 3 | 2021 | 422 | 1.230 |
Why?
| | Solubility | 1 | 2024 | 79 | 0.890 |
Why?
| | T-Lymphocytes | 2 | 2024 | 340 | 0.820 |
Why?
| | Protein Kinase Inhibitors | 1 | 2024 | 226 | 0.780 |
Why?
| | Early Growth Response Protein 1 | 1 | 2021 | 34 | 0.730 |
Why?
| | Graft Survival | 2 | 2022 | 160 | 0.720 |
Why?
| | Lymphocyte Activation | 1 | 2021 | 172 | 0.710 |
Why?
| | Graft Rejection | 2 | 2022 | 177 | 0.700 |
Why?
| | Skin Transplantation | 1 | 2021 | 44 | 0.690 |
Why?
| | Pancreatic Neoplasms | 3 | 2012 | 213 | 0.640 |
Why?
| | Antineoplastic Agents | 1 | 2023 | 1219 | 0.450 |
Why?
| | Mice | 11 | 2024 | 5875 | 0.440 |
Why?
| | Blood Preservation | 2 | 2012 | 27 | 0.440 |
Why?
| | Plasma | 2 | 2012 | 45 | 0.430 |
Why?
| | Kidney Transplantation | 2 | 2024 | 192 | 0.360 |
Why?
| | Blood Component Transfusion | 1 | 2010 | 8 | 0.350 |
Why?
| | Mice, Inbred BALB C | 2 | 2021 | 310 | 0.340 |
Why?
| | Animals | 13 | 2024 | 13384 | 0.340 |
Why?
| | Extracellular Matrix Proteins | 1 | 2010 | 69 | 0.330 |
Why?
| | Cell Line, Tumor | 4 | 2024 | 1427 | 0.320 |
Why?
| | GATA4 Transcription Factor | 3 | 2008 | 11 | 0.300 |
Why?
| | Recombinant Proteins | 1 | 2010 | 483 | 0.300 |
Why?
| | Reactive Oxygen Species | 1 | 2010 | 422 | 0.280 |
Why?
| | Povidone-Iodine | 1 | 2024 | 8 | 0.230 |
Why?
| | Peritoneal Lavage | 1 | 2024 | 5 | 0.230 |
Why?
| | Abdominal Abscess | 1 | 2024 | 15 | 0.230 |
Why?
| | Anti-Infective Agents, Local | 1 | 2024 | 30 | 0.230 |
Why?
| | Cytokines | 2 | 2021 | 622 | 0.220 |
Why?
| | Tissue and Organ Procurement | 1 | 2024 | 49 | 0.220 |
Why?
| | Appendicitis | 1 | 2024 | 66 | 0.220 |
Why?
| | Tissue Donors | 1 | 2024 | 126 | 0.210 |
Why?
| | Proteomics | 2 | 2017 | 324 | 0.210 |
Why?
| | T-Box Domain Proteins | 2 | 2008 | 14 | 0.210 |
Why?
| | DNA Damage | 1 | 2024 | 305 | 0.200 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2023 | 132 | 0.190 |
Why?
| | Jurkat Cells | 1 | 2021 | 28 | 0.190 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2023 | 164 | 0.190 |
Why?
| | Protein Stability | 1 | 2021 | 45 | 0.180 |
Why?
| | Mice, Inbred NOD | 1 | 2021 | 92 | 0.180 |
Why?
| | Mice, SCID | 1 | 2021 | 182 | 0.180 |
Why?
| | Mutation, Missense | 1 | 2021 | 107 | 0.180 |
Why?
| | DNA | 2 | 2023 | 549 | 0.170 |
Why?
| | Transcription, Genetic | 1 | 2021 | 378 | 0.170 |
Why?
| | Disease Models, Animal | 2 | 2024 | 1469 | 0.160 |
Why?
| | Flow Cytometry | 1 | 2021 | 401 | 0.160 |
Why?
| | GATA6 Transcription Factor | 1 | 2008 | 3 | 0.150 |
Why?
| | Humans | 11 | 2024 | 52205 | 0.150 |
Why?
| | Mice, Inbred C57BL | 2 | 2021 | 1880 | 0.140 |
Why?
| | Postoperative Complications | 1 | 2024 | 1066 | 0.140 |
Why?
| | Heart Defects, Congenital | 2 | 2008 | 617 | 0.130 |
Why?
| | Blood Proteins | 1 | 2017 | 84 | 0.130 |
Why?
| | Whole-Body Irradiation | 1 | 2017 | 127 | 0.130 |
Why?
| | Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase | 1 | 2016 | 7 | 0.130 |
Why?
| | Procollagen-Proline Dioxygenase | 1 | 2016 | 9 | 0.130 |
Why?
| | Heart | 1 | 2008 | 345 | 0.130 |
Why?
| | Cell Proliferation | 2 | 2010 | 1023 | 0.130 |
Why?
| | Autoantigens | 1 | 2016 | 53 | 0.120 |
Why?
| | Endoplasmic Reticulum | 1 | 2016 | 111 | 0.120 |
Why?
| | Proteome | 1 | 2017 | 169 | 0.120 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2015 | 25 | 0.120 |
Why?
| | Protein Processing, Post-Translational | 1 | 2016 | 152 | 0.120 |
Why?
| | Proto-Oncogene Proteins c-ret | 1 | 2015 | 33 | 0.120 |
Why?
| | Collagen | 1 | 2016 | 211 | 0.120 |
Why?
| | Mutation | 4 | 2012 | 1347 | 0.110 |
Why?
| | Heart Diseases | 1 | 2007 | 214 | 0.110 |
Why?
| | Thyroid Neoplasms | 1 | 2015 | 116 | 0.110 |
Why?
| | Nuclear Proteins | 1 | 2015 | 245 | 0.110 |
Why?
| | Macaca | 1 | 2012 | 9 | 0.100 |
Why?
| | Sirtuin 1 | 1 | 2012 | 29 | 0.100 |
Why?
| | Erythrocyte Transfusion | 1 | 2012 | 52 | 0.090 |
Why?
| | Transcription Factors | 2 | 2005 | 566 | 0.090 |
Why?
| | Injections, Intravenous | 1 | 2010 | 135 | 0.080 |
Why?
| | Histones | 1 | 2012 | 314 | 0.080 |
Why?
| | Protein Binding | 2 | 2010 | 666 | 0.080 |
Why?
| | Diet, High-Fat | 1 | 2012 | 236 | 0.080 |
Why?
| | Embryo, Mammalian | 1 | 2010 | 66 | 0.080 |
Why?
| | Fibronectins | 1 | 2010 | 37 | 0.080 |
Why?
| | Neoplasm Metastasis | 1 | 2010 | 239 | 0.080 |
Why?
| | Lymphatic Metastasis | 1 | 2010 | 212 | 0.080 |
Why?
| | Peritoneal Neoplasms | 1 | 2010 | 65 | 0.080 |
Why?
| | Cell Movement | 1 | 2010 | 268 | 0.080 |
Why?
| | Neovascularization, Pathologic | 1 | 2010 | 151 | 0.080 |
Why?
| | Gene Expression Regulation, Developmental | 3 | 2012 | 137 | 0.070 |
Why?
| | Endothelial Cells | 1 | 2010 | 261 | 0.070 |
Why?
| | Antioxidants | 1 | 2010 | 256 | 0.070 |
Why?
| | Fibroblasts | 1 | 2010 | 354 | 0.070 |
Why?
| | Oxidative Stress | 1 | 2010 | 804 | 0.060 |
Why?
| | Time Factors | 2 | 2024 | 2948 | 0.060 |
Why?
| | Therapeutic Irrigation | 1 | 2024 | 29 | 0.060 |
Why?
| | Heart Valve Diseases | 1 | 2005 | 53 | 0.060 |
Why?
| | Donor Selection | 1 | 2024 | 20 | 0.060 |
Why?
| | Receptors, Cell Surface | 1 | 2005 | 113 | 0.060 |
Why?
| | Tissue Adhesions | 1 | 2024 | 35 | 0.060 |
Why?
| | Apoptosis | 1 | 2010 | 1114 | 0.060 |
Why?
| | Female | 7 | 2024 | 28061 | 0.060 |
Why?
| | Aortic Valve | 1 | 2005 | 123 | 0.050 |
Why?
| | COS Cells | 3 | 2012 | 73 | 0.050 |
Why?
| | Mass Spectrometry | 2 | 2017 | 292 | 0.050 |
Why?
| | Xenopus Proteins | 1 | 2003 | 29 | 0.050 |
Why?
| | Delayed Graft Function | 1 | 2022 | 11 | 0.050 |
Why?
| | Cold Ischemia | 1 | 2022 | 11 | 0.050 |
Why?
| | Male | 6 | 2024 | 26656 | 0.050 |
Why?
| | Creatinine | 1 | 2022 | 149 | 0.050 |
Why?
| | HeLa Cells | 2 | 2008 | 260 | 0.050 |
Why?
| | Base Sequence | 2 | 2007 | 640 | 0.050 |
Why?
| | Risk Assessment | 1 | 2024 | 1322 | 0.040 |
Why?
| | Signal Transduction | 2 | 2017 | 1669 | 0.040 |
Why?
| | Embryo Loss | 1 | 2008 | 2 | 0.040 |
Why?
| | Fetal Growth Retardation | 1 | 2008 | 40 | 0.040 |
Why?
| | Pregnancy | 2 | 2012 | 2669 | 0.040 |
Why?
| | Alleles | 1 | 2008 | 276 | 0.040 |
Why?
| | Myocytes, Cardiac | 1 | 2008 | 129 | 0.030 |
Why?
| | Genotype | 1 | 2008 | 566 | 0.030 |
Why?
| | Conserved Sequence | 1 | 2007 | 53 | 0.030 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2017 | 96 | 0.030 |
Why?
| | Macaca mulatta | 1 | 2017 | 92 | 0.030 |
Why?
| | Family Health | 1 | 2007 | 78 | 0.030 |
Why?
| | Gamma Rays | 1 | 2017 | 49 | 0.030 |
Why?
| | Exons | 1 | 2007 | 102 | 0.030 |
Why?
| | Transcriptional Activation | 1 | 2007 | 122 | 0.030 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2017 | 182 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2017 | 232 | 0.030 |
Why?
| | Cyclophilins | 1 | 2016 | 9 | 0.030 |
Why?
| | Genetic Testing | 1 | 2007 | 129 | 0.030 |
Why?
| | Hydroxylation | 1 | 2016 | 62 | 0.030 |
Why?
| | Osteogenesis Imperfecta | 1 | 2016 | 37 | 0.030 |
Why?
| | Risk Factors | 1 | 2024 | 3867 | 0.030 |
Why?
| | Myocardium | 1 | 2008 | 453 | 0.030 |
Why?
| | Extracellular Matrix | 1 | 2016 | 111 | 0.030 |
Why?
| | Pedigree | 2 | 2005 | 125 | 0.030 |
Why?
| | Treatment Outcome | 1 | 2024 | 5405 | 0.030 |
Why?
| | DNA Mutational Analysis | 2 | 2005 | 180 | 0.030 |
Why?
| | Phosphorylation | 1 | 2015 | 527 | 0.030 |
Why?
| | United States | 1 | 2024 | 5177 | 0.030 |
Why?
| | Cell Line | 1 | 2016 | 1022 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2016 | 879 | 0.030 |
Why?
| | p300-CBP Transcription Factors | 1 | 2012 | 6 | 0.030 |
Why?
| | Indoles | 1 | 2015 | 278 | 0.020 |
Why?
| | Catalytic Domain | 1 | 2012 | 60 | 0.020 |
Why?
| | Acetylation | 1 | 2012 | 95 | 0.020 |
Why?
| | Substrate Specificity | 1 | 2012 | 193 | 0.020 |
Why?
| | Bone and Bones | 1 | 2016 | 494 | 0.020 |
Why?
| | Histone Deacetylases | 1 | 2012 | 51 | 0.020 |
Why?
| | Platelet-Derived Growth Factor | 1 | 2012 | 23 | 0.020 |
Why?
| | Lysine | 1 | 2012 | 89 | 0.020 |
Why?
| | Erythrocytes | 1 | 2012 | 70 | 0.020 |
Why?
| | Adult | 2 | 2024 | 14128 | 0.020 |
Why?
| | Chemokine CCL2 | 1 | 2012 | 69 | 0.020 |
Why?
| | Fetus | 1 | 2012 | 194 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 235 | 0.020 |
Why?
| | Neoplasms, Experimental | 1 | 2012 | 112 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 580 | 0.020 |
Why?
| | Blotting, Western | 1 | 2012 | 590 | 0.020 |
Why?
| | Tumor Cells, Cultured | 1 | 2012 | 456 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2015 | 855 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2022 | 6571 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2012 | 395 | 0.020 |
Why?
| | Blood Platelets | 1 | 2012 | 256 | 0.020 |
Why?
| | Middle Aged | 1 | 2024 | 13005 | 0.020 |
Why?
| | Adenocarcinoma | 1 | 2012 | 404 | 0.020 |
Why?
| | Liver | 1 | 2012 | 1156 | 0.020 |
Why?
| | Lod Score | 1 | 2005 | 7 | 0.020 |
Why?
| | Receptor, Notch1 | 1 | 2005 | 5 | 0.020 |
Why?
| | Core Binding Factor Alpha 1 Subunit | 1 | 2005 | 46 | 0.020 |
Why?
| | In Situ Hybridization | 1 | 2005 | 64 | 0.020 |
Why?
| | Chromosomes, Human, Pair 9 | 1 | 2005 | 20 | 0.020 |
Why?
| | Calcinosis | 1 | 2005 | 51 | 0.010 |
Why?
| | Repressor Proteins | 1 | 2005 | 155 | 0.010 |
Why?
| | Precipitin Tests | 1 | 2003 | 31 | 0.010 |
Why?
| | Chromosomes, Human, Pair 8 | 1 | 2003 | 15 | 0.010 |
Why?
| | Frameshift Mutation | 1 | 2003 | 18 | 0.010 |
Why?
| | Electrophoretic Mobility Shift Assay | 1 | 2003 | 74 | 0.010 |
Why?
| | Chromosome Mapping | 1 | 2003 | 154 | 0.010 |
Why?
| | Neoplasm Proteins | 1 | 2005 | 333 | 0.010 |
Why?
| | Homeodomain Proteins | 1 | 2003 | 80 | 0.010 |
Why?
| | Binding Sites | 1 | 2003 | 376 | 0.010 |
Why?
| | Phenotype | 1 | 2005 | 787 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2005 | 1131 | 0.010 |
Why?
| | Child | 1 | 2005 | 7143 | 0.010 |
Why?
|
|
Burdine's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|